Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 3Phase 3 2Phase 1/2 1

Status

Unknown 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 129Radiotherapy 94Carboplatin 82Fluorouracil 77Paclitaxel 76Cyclophosphamide 76Gemcitabine 71Capecitabine 66Docetaxel 64Doxorubicin 59Oxaliplatin 57Etoposide 57Leucovorin 48Vincristine 46Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Pemetrexed 27Neoadjuvant Therapy 26Irinotecan 25Tamoxifen 24Prednisone 23Methotrexate 21Rituximab 19Vinorelbine 18Radiotherapy, Intensity-Modulated 18Peripheral Blood Stem Cell Transplantation 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Gene Expression Profiling × Clear all
NCT01099423 2017-02-08

SURTIME

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Unknown
99 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00553124 2014-01-10

Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
3,400 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡